Incyte Corporation (INCY) – What Are Researchers Saying About This Stock?

Shares of Incyte Corporation (NASDAQ:INCY) have earned an average rating of “Hold” from the twenty-five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $132.90.

INCY has been the subject of several recent analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, September 11th. Weiss Ratings lowered shares of Incyte from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, October 23rd. Guggenheim upped their target price on shares of Incyte from $136.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Truist Financial increased their target price on shares of Incyte from $105.00 to $115.00 and gave the company a “hold” rating in a report on Wednesday, October 14th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Incyte in a research report on Tuesday.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Incyte Trading Up 3.1%

NASDAQ INCY opened at $120.39 on Friday. The business’s 50 day moving average is $120.49 and its two-hundred day moving average is $108.14. Incyte has a 12-month low of $89.25 and a 12-month high of $132.60. The stock has a market capitalization of $24.40 billion, a price-to-earnings ratio of 64.04, a PEG ratio of 4.98 and a beta of 0.74.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same period last year, the firm earned $2.26 EPS. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. Equities analysts forecast that Incyte will post 1.97 earnings per share for the current fiscal year.

Insider Activity

In other Incyte news, insider Pablo Cagnoni sold 2,642 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the sale, the insider owned 183,200 shares of the company’s stock, valued at $20,648,472. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Incyte during the second quarter worth $2,044,189,000. Wellington Management Group LLP raised its position in shares of Incyte by 9.5% in the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock valued at $405,321,000 after purchasing an additional 309,385 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Incyte by 10.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after purchasing an additional 187,354 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Incyte by 2.2% during the 1st quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock valued at $163,869,000 after buying an additional 37,790 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Incyte during the 2nd quarter valued at approximately $182,054,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.